• 1. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 2. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 3. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoyl derivatives

Research Briefing on 3-Bromo-2-fluoro-5-methylbenzaldehyde (CAS: 1257665-03-4) in Chemical Biology and Pharmaceutical Applications

3-Bromo-2-fluoro-5-methylbenzaldehyde (CAS: 1257665-03-4) is a halogenated aromatic aldehyde that has garnered significant attention in recent chemical biology and pharmaceutical research due to its versatile reactivity and potential as a building block for drug discovery. This compound's unique structural features, including the bromo and fluoro substituents, make it a valuable intermediate in the synthesis of complex molecules, particularly in the development of kinase inhibitors and other targeted therapeutics. Recent studies have explored its applications in medicinal chemistry, with a focus on its role in fragment-based drug design and as a precursor for bioactive molecules.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers utilized 3-Bromo-2-fluoro-5-methylbenzaldehyde as a key intermediate in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The compound's halogen atoms facilitated efficient cross-coupling reactions, enabling the rapid generation of a diverse library of analogs. The study reported that derivatives incorporating this scaffold exhibited improved selectivity profiles compared to earlier-generation BTK inhibitors, with IC50 values in the low nanomolar range. These findings highlight the compound's potential in addressing drug resistance mechanisms observed in hematological malignancies.

Another significant application emerged from recent work in positron emission tomography (PET) tracer development. A 2024 Nature Communications paper described the use of 1257665-03-4 as a precursor for fluorine-18 labeled compounds, capitalizing on the presence of the fluorine atom for efficient isotopic exchange. The resulting PET tracers demonstrated excellent blood-brain barrier penetration and specific binding to neurodegenerative disease targets, suggesting promising diagnostic applications for Alzheimer's and Parkinson's diseases. The research team noted that the methyl group at the 5-position contributed to enhanced metabolic stability of the final radiotracers.

From a synthetic chemistry perspective, recent advances in continuous flow chemistry have improved the scalability and safety of processes involving 3-Bromo-2-fluoro-5-methylbenzaldehyde. A 2023 Organic Process Research & Development publication detailed an optimized continuous manufacturing approach that reduced hazardous waste generation by 40% compared to traditional batch methods while maintaining high purity (>99.5%). This technological advancement addresses growing concerns about sustainable pharmaceutical manufacturing and could facilitate larger-scale production of derivatives for clinical evaluation.

The compound's mechanism of action in various biological contexts continues to be elucidated. Recent proteomics studies have identified several protein targets that interact with 1257665-03-4-derived compounds, including unexpected off-target effects that may explain previously observed toxicities. These findings, published in ACS Chemical Biology in early 2024, have prompted structural modifications to improve target specificity while maintaining potency. Computational modeling suggests that the bromo and fluoro substituents create a unique electronic environment that influences binding affinity to multiple kinase domains.

Looking forward, the pharmaceutical industry appears poised to expand applications of 3-Bromo-2-fluoro-5-methylbenzaldehyde beyond its current uses. Patent filings in 2024 reveal growing interest in its incorporation into PROTACs (proteolysis targeting chimeras) and other targeted protein degradation platforms. The compound's ability to serve as a linker between warhead and E3 ligase-binding moieties, while maintaining favorable pharmacokinetic properties, positions it as a valuable tool in this emerging therapeutic modality. Current clinical pipelines include at least three investigational drugs derived from this scaffold that are expected to enter Phase I trials within the next two years.

• 93777-26-5(2-Fluoro-5-bromobenzaldehyde)
• 903875-64-9(5-Bromo-2-fluoro-3-methylbenzaldehyde)
• 398456-82-1(3-Bromo-2,6-difluorobenzaldehyde)
• 149947-15-9(3-Bromo-2-fluorobenzaldehyde)
• 1378865-38-3(5-Bromo-2,4-difluoro-3-methylbenzaldehyde)
• 644985-24-0(4-Bromo-2,3-difluorobenzaldehyde)
• 77771-02-9(3-Bromo-4-fluorobenzaldehyde)
• 477535-40-3(3,5-Dibromo-2-fluorobenzaldehyde)
• 357405-75-5(4-Bromo-2,5-difluorobenzaldehyde)
• 870703-68-7(3,6-Dibromo-2-fluorobenzaldehyde)